Clopidogrel-Statin Interaction: a Missing Links

Introduction: The use of clopidogrel is associated with a large variability in the response to this drug, wherein the results of the numerous studies indicate that even one out of three patients can be placed in the category of non responder. Corresponding section headings: Among the many causes of modified pharmacodynamic effects of clopidogrel, special attention is addressed to the possible clopidogrel-statin interaction. Numerous studies have focused on this problem, but it still seems to be missing the right answer. Conclusion: This paper reviews some of the most important facts regarding concomitant use of clopidogrel and statins, and specific issues to be addressed for safe treatment of patients.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5937/HPIMJ1602395T
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population

  2016cited by this paper
• Men with lower HDL cholesterol levels have significant increment of soluble CD40 ligand and high-sensitivity CRP levels following the cessation of long-term clopidogrel therapy.

  2015cited by this paper
• Clopidogrel cessation triggers aspirin rebound in patients with coronary stent

  2014cited by this paper
• Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.

  2013cited by this paper
• Advantages and limitations of clopidogrel response testing methods.

  2012cited by this paper
• Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.

  2012cited by this paper
• 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

  2011cited by this paper
• Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events.

  2011cited by this paper
• PCI and clopidogrel: antiplatelet responsiveness and patient characteristics

  2011cited by this paper
• Guidelines on myocardial revascularization.

  2010cited by this paper
• Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

  2010cited by this paper
• Guidelines on myocardial revascularization.

  2010cited by this paper
• [The importance of tests applied to evaluate the effectiveness of antiplatelet therapy in patients with recurrent coronary stent thrombosis].

  2009cited by this paper
• 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)

  2009cited by this paper
• Thienopyridine resistance among patients undergoing intracoronary stent implantation and treated with dual antiplatelet therapy: assessment of some modifying factors.

  2008cited by this paper
• High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.

  2008cited by this paper
• Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy.

  2008cited by this paper
• Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement

  2007cited by this paper
• Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

  2007cited by this paper
• A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.

  2006cited by this paper
• Abstract 3287: Lack of Evidence of a Clopidogrel-Statin Interaction in the CHARISMA Trial

  2006cited by this paper
• Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel

  2006cited by this paper
• The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease

  2005cited by this paper
• Not all statins interfere with clopidogrel during antiplatelet therapy

  2005cited by this paper
• Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

  2004cited by this paper
• Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance

  2004cited by this paper
• Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.

  2004cited by this paper
• ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin

  2004cited by this paper
• Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study

  2004cited by this paper
• Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction

  2003cited by this paper
• Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

  2003cited by this paper
• Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.

  2003cited by this paper
• Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial

  2003cited by this paper
• The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.

  2003cited by this paper
• Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study.

  2003cited by this paper
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)

  2003cited by this paper
• A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin

  2002cited by this paper
• Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

  2002cited by this paper
• New insights into the pharmacodynamic and pharmacokinetic properties of statins.

  1999cited by this paper

• Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome

  2022cites this paper